L. M. Wheatley and A. Togias, Clinical practice. Allergic rhinitis, N Engl J Med, vol.372, pp.456-63, 2015.

J. Bousquet, N. Khaltaev, and A. A. Cruz, Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen), Allergy, vol.63, issue.86, pp.8-160, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00596392

V. Bauchau and S. R. Durham, Prevalence and rate of diagnosis of allergic rhinitis in Europe, Eur Respir J, vol.24, pp.758-64, 2004.

J. M. Klossek, I. Annesi-maesano, C. Pribil, and A. Didier, INSTANT: national survey of allergic rhinitis in a French adult population based-sample, Presse Med, vol.38, pp.1220-1229, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00595791

N. Bhattacharyya, Functional limitations and workdays lost associated with chronic rhinosinusitis and allergic rhinitis, Am J Rhinol Allergy, vol.26, pp.120-122, 2012.

G. Majani, I. Baiardini, and A. Giardini, Health-related quality of life assessment in young adults with seasonal allergic rhinitis, Allergy, vol.56, pp.313-320, 2001.

E. O. Meltzer, Allergic rhinitis: burden of illness, quality of life, comorbidities, and control, Immunol Allergy Clin North Am, vol.36, pp.235-283, 2016.

C. Cingi, P. Gevaert, and R. Mosges, Multi-morbidities of allergic rhinitis in adults: European academy of allergy and clinical immunology task force report, Clin Transl Allergy, vol.7, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01760907

G. D'-amato, F. T. Spieksma, and G. Liccardi, Pollen-related allergy in Europe, Allergy, vol.53, pp.567-78, 1998.

R. C. Panzani, P. Mercier, and Y. Delord, Prevalence of patent and latent atopy among a general normal adult population in the south east of France by RAST investigation and correlation with circulating total IgE levels, Allergol Immunopathol (Madr), vol.21, pp.211-220, 1993.

A. Meadows, B. Kaambwa, and N. Novielli, A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis, Health Technol Assess, vol.17, pp.1-322, 2013.

M. A. Calderon, L. Cox, and T. B. Casale, The effect of a new communication template on anticipated willingness to initiate or resume allergen immunotherapy: an internet-based patient survey, Allergy Asthma Clin Immunol, vol.11, p.17, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01156541

G. Passalacqua, G. W. Canonica, and D. Bagnasco, Benefit of SLIT and SCIT for allergic rhinitis and asthma, Curr Allergy Asthma Rep, vol.16, p.88, 2016.

L. S. Cox, T. B. Casale, and A. S. Nayak, Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE, J Allergy Clin Immunol, vol.130, p.1321, 2012.

A. Didier, H. J. Malling, and M. Worm, Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis, J Allergy Clin Immunol, vol.120, pp.1338-1383, 2007.

A. Didier, M. Worm, and F. Horak, Sustained 3-year efficacy of pre-and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis, J Allergy Clin Immunol, vol.128, pp.559-66, 2011.

N. Franzke, I. Schafer, and K. Jost, A new instrument for the assessment of patient-defined benefit in the treatment of allergic rhinitis, Allergy, vol.66, pp.665-70, 2011.

P. Demoly, M. Aubier, F. De-blay, F. Wessel, P. Clerson et al., Evaluation of patients' expectations and benefits in the treatment of allergic rhinitis with a new tool: the patient benefit index-the benefica study, Allergy Asthma Clin Immunol, vol.11, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01144165

J. Bousquet, P. Van-cauwenberge, and N. Khaltaev, Allergic rhinitis and its impact on asthma, J Allergy Clin Immunol, vol.108, pp.147-334, 2001.
URL : https://hal.archives-ouvertes.fr/hal-02099400

, World Health Organization. WHO Collaborating Centre for Drug Statistics Methodology: guidelines for ATC classification and DDD assignment. Oslo: WHO-CCDSM, 2017.

A. Didier, M. Melac, A. Montagut, M. Lheritier-barrand, A. Tabar et al., Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy, Allergy, vol.64, pp.166-71, 2009.

A. Didier and B. Bons, Safety and tolerability of 5-grass pollen tablet sublingual immunotherapy: pooled analysis and clinical review, Expert Opin Drug Saf, vol.14, p.68, 2015.

K. Shah-hosseini, K. Mioc, M. Hadler, E. Karagiannis, and R. Mosges, Optimum treatment strategies for polyallergic patients-analysis of a large observational trial, Curr Med Res Opin, vol.31, pp.2249-59, 2015.

D. Antolin, T. Valbuena, A. Valls, S. Garrido, C. Blanco et al., One season of treatment with 5 grass pollen tablets in adults demonstrated a reduction in disease symptoms and impacts. Findings of the SMILE study, European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting, 2013.